Paul Crispen, MD

Trials

Studies that name Paul Crispen, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:31 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT06722807 · ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses

  University of Florida · suspended · Renal Cell Carcinoma (RCC) · principal investigator
• Ph2
  NCT06488222 · Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

  University of Florida · recruiting · Bladder Cancer · principal investigator
• Ph2
  NCT05766514 · Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

  University of Florida · withdrawn · Acute Myeloid Leukemia, Myelodysplastic Syndromes · principal investigator
• Ph2
  NCT03658304 · Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

  University of Florida · completed · Urothelial Carcinoma · principal investigator
• Ph3
  NCT03016130 · Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)

  University of Florida · terminated · Leukemia, Myelodysplastic Syndromes · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.